iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC [Yahoo! Finance]
iTeos Therapeutics, Inc. (ITOS)
Company Research
Source: Yahoo! Finance
The double-blind, placebo-controlled study aims to compare the combination of belrestotug and dostarlimab against placebo plus pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC. It will enrol around 1,000 patients in North and South America, Asia and Europe. Progression-free survival and overall survival are the trial's primary endpoints. Participants will be randomised at a 1:1 ratio to receive either an intravenous infusion of the belrestotug plus dostarlimab regimen or placebo plus pembrolizumab. Last month, iTeos published interim analysis data from the Phase II GALAXIES Lung-201 study showing that the belrestotug-dostarlimab combination surpassed the pre-defined efficacy criteria for clinically relevant activity. It also demonstrated an acceptable safety profile consistent with the TIGIT:PD-1 class. In addition, the treatment regimen offered "clinically meaningful" tumour reduction at every dose com
Show less
Read more
Impact Snapshot
Event Time:
ITOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITOS alerts
High impacting iTeos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ITOS
News
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.MarketBeat
- iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung CancerGlobeNewswire
- Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package? [Yahoo! Finance]Yahoo! Finance
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target raised by analysts at HC Wainwright from $44.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
ITOS
Earnings
- 5/10/24 - Miss
ITOS
Sec Filings
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- ITOS's page on the SEC website